VECT News

Just two IPOs priced this past week, raising $222 million as the US IPO market continued to cool down. They were joined by eight SPACs that raised $1.5 million. The IPO pipeline remained active, with 13 IPOs and 14 SPACs submitting initial filings this week. Swiss rare disease biotech VectivBio Holding (VECT) priced at the midpoint to raise $128 million at a...read more

VectivBio Holding, a Swiss Phase 3 biotech developing therapies for rare gastrointestinal disorders, raised $128 million by offering 7.5 million shares at $17, within the range of $16 to $18. At pricing, the company commands a fully diluted market value of $634 million. VectivBio's current product pipeline is focused on rare gastrointestinal disorders. Its candidate,...read more

VectivBio Holding, a Swiss Phase 3 biotech developing therapies for rare gastrointestinal disorders, announced terms for its IPO on Monday. The Basel, Switzerland-based company plans to raise $128 million by offering 7.5 million shares at a price range of $16 to $18. At the midpoint of the proposed range, VectivBio Holding would command a fully diluted market value of $634...read more

The IPO market stayed busy this past week, with 11 IPOs raising $3.0 billion. The week’s IPOs were joined by 24 SPACs that raised $8.4 billion. New filers continued to fill the IPO pipeline, with 8 IPOs and 46 SPACs submitting initial filings. Chinese IoT platform developer Tuya (TUYA) priced above the range to raise $915 million at an $11.8 billion...read more